BridgeBio Pharma Inc.
BBIO | NASDAQ
$75.40
+$0.45 (+0.60%)
Nov 2, 2026, 1:39 PM ET · Market open
Market Data
Market Cap $14.69B
Enterprise Value $15.61B
Beta 0.97
Average Volume 3.05M
Shares Outstanding (Diluted) 196.03M
Shares Change YoY 2.89%
Institutional Ownership N/A
Exchange NASDAQ
ISIN US10806X1028
Price Performance
Price Change 1M 12.1%
Price Change 3M -5.7%
Price Change 6M 9.3%
Price Change YTD -1.4%
Price Change 1Y 21.6%
Price Change 3Y 161.5%
Price Change 5Y 50.8%
1M CAGR (ann.) 12.5%
1Y CAGR (ann.) 12.5%
5Y CAGR (ann.) 9.8%
All-Time CAGR 14.6%
Valuation
PE Ratio -24.65
Forward PE 560.56
PEG Ratio -0.74
Forward PEG 1.16
PS Ratio 15.50
Forward PS 8.80
PB Ratio -8.81
P/FCF Ratio -39.15
P/Adj. FCF Ratio -27.85
P/OCF Ratio -39.87
EV/Sales 16.51
EV/EBIT -35.05
EV/EBITDA -35.42
EV/FCF -41.70
Earnings Yield -4.1%
FCF Yield -2.5%
Adj. FCF Yield -3.6%
Financial Health
Net Debt $938.56M
Total Debt $2.49B
Cash & Short-Term Investments $1.54B
Total Assets $2.16B
Current Ratio 2.09
Quick Ratio 2.03
Debt / Equity Ratio -1.50
Debt / EBITDA -5.66
Debt / FCF -6.66
OCF / Debt -0.15
Interest Coverage -3.07
Altman Z-Score -0.07
Piotroski F-Score 4
Margins & Profitability
Gross Profit Margin 93.5%
Operating Profit Margin -43.4%
EBITDA Margin -46.6%
Net Profit Margin -60.3%
FCF Margin -39.6%
Adj. FCF Margin -55.6%
SBC / Revenue 16.1%
SBC Impact (per share) -40.6%
Returns
Return on Assets -26.4%
Return on Equity 26.8%
Return on Invested Capital -23.6%
Return on Capital Employed -34.6%
Return on Tangible Assets -26.7%
Historical Growth (CAGR)
Revenue CAGR 3Y 364.6%
Revenue CAGR 5Y 75.4%
Revenue CAGR 10Y N/A
EPS CAGR 3Y -9.8%
EPS CAGR 5Y 1.8%
EPS CAGR 10Y N/A
FCF CAGR 3Y 8.6%
FCF CAGR 5Y 1.9%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Buy
Analyst Count 17
EPS Growth Next 3Y 110.2%
Revenue Growth Next 3Y 58.0%
Earnings Date Feb 23, 2027
EPS Estimate (next Q) -$0.59
EPS Growth Est (next Q) -40.7%
Revenue Est (next Q) $309.39M
Revenue Growth Est (next Q) 100.7%
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $112.83
Price Target Upside 50.5%
Cash Flow
Operating Cash Flow $-368.97M
Free Cash Flow $-374.31M
Adj. Free Cash Flow $-526.12M
FCF Per Share -$1.91
OCF Per Share -$1.88
OCF/S Ratio -39.0%
Income Statement
Revenue $945.54M
Gross Profit $884.2M
Operating Income $-409.91M
EBITDA $-440.58M
Net Income $-570.21M
EPS (Diluted) -$3.04
Revenue / Employee $1.13M
Profit / Employee $-679.63K
Employees 839
Add to Watchlist
Select watchlists to add or remove BBIO